We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+8.62%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.71B
AUM Growth
+$201M
Cap. Flow
+$66M
Cap. Flow %
1.4%
Top 10 Hldgs %
37.6%
Holding
120
New
15
Increased
43
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$135M
2
AZN icon
AstraZeneca
AZN
+$85.6M
3
BAX icon
Baxter International
BAX
+$72.7M
4
AVTR icon
Avantor
AVTR
+$60.9M
5
UNH icon
UnitedHealth
UNH
+$55.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$126M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$92.2M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$39.7M
4
EXAS
Exact Sciences
EXAS
+$35.2M
5
CMPS
Compass Pathways
CMPS
+$34.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.5%
3 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
51
Altimmune
ALT
$560M
$25.3M 0.54%
2,765,000
+597,100
+28% +$6.34M
VRDN icon
52
Viridian Therapeutics
VRDN
$2.14B
$25.3M 0.54%
+1,278,261
New +$23.8M
GBT
53
DELISTED
Global Blood Therapeutics, Inc.
GBT
$25.2M 0.54%
+862,000
New +$26.7M
CCXI
54
DELISTED
ChemoCentryx, Inc.
CCXI
$23.5M 0.5%
+644,400
New +$22.6M
SIBN icon
55
SI-BONE Inc
SIBN
$789M
$21.9M 0.47%
987,400
+156,200
+19% +$3.36M
CYT
56
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$21M 0.45%
1,849,538
+166,097
+10% +$2.53M
ALPN
57
DELISTED
Alpine Immune Sciences Inc
ALPN
$18.6M 0.4%
1,345,000
-587,000
-30% -$7.27M
RLMD icon
58
Relmada Therapeutics
RLMD
$546M
$16.5M 0.35%
+731,536
New +$16.3M
SCYX icon
59
SCYNEXIS
SCYX
$35.9M
$13.7M 0.29%
279,910
+22,410
+9% +$1.1M
IPSC icon
60
Century Therapeutics
IPSC
$364M
$13.5M 0.29%
851,522
+112,253
+15% +$2.11M
PHAS
61
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$11.5M 0.24%
4,405,000
– –
HYPR icon
62
Hyperfine
HYPR
$92M
$11M 0.23%
+1,514,410
New +$12M
S icon
63
SentinelOne
S
$6.31B
$10.5M 0.22%
208,000
+8,000
+4% +$469K
LENZ
64
LENZ Therapeutics
LENZ
$182M
$8.82M 0.19%
101,429
-5,570
-5% -$461K
REUN
65
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$7.88M 0.17%
641,000
-75,200
-10% -$1.61M
TNGX icon
66
Tango Therapeutics
TNGX
$4.31B
$7.71M 0.16%
705,000
+405,000
+135% +$4.87M
ACAD icon
67
Acadia Pharmaceuticals
ACAD
$4.42B
$7M 0.15%
300,000
-250,000
-45% -$5.03M
TIL icon
68
Instil Bio
TIL
$49.2M
$6.98M 0.15%
20,407
– –
TRML
69
DELISTED
Tourmaline Bio
TRML
$6.96M 0.15%
45,504
+4
+0% +$592
DH icon
70
Definitive Healthcare
DH
$73M
$6.83M 0.14%
+250,000
New +$8.75M
EQRX
71
DELISTED
EQRx, Inc. Common Stock
EQRX
$6.82M 0.14%
+1,000,000
New +$9.44M
CMAX
72
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$6.35M 0.13%
27,580
– –
CMPX icon
73
Compass Therapeutics
CMPX
$367M
$6.34M 0.13%
+2,000,000
New +$6.63M
GLUE icon
74
Monte Rosa Therapeutics
GLUE
$1.84B
$6.13M 0.13%
300,000
– –
HOWL icon
75
Werewolf Therapeutics
HOWL
$21.5M
$5.78M 0.12%
485,000
-140,120
-22% -$2.11M
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2021 Portfolio in Review

As of Q4 2021, Avidity Partners Management held 120 positions worth $4.71B, up 4.5% from $4.51B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Avidity Partners Management's Q4 2021 filing shows 15 new, 43 increased, 17 reduced and 23 closed positions. Its largest new stake was Elevance Health: 321,000 shares worth $149M. The largest sale was Vertex Pharmaceuticals, an estimated $126M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Financials and Technology.

  • Avidity Partners Management's largest Q4 2021 buy was Elevance Health: 321,000 shares worth $149M.
  • Avidity Partners Management added most to AstraZeneca in Q4 2021, an estimated $85.6M increase.
  • Avidity Partners Management's biggest Q4 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $126M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q4 2021, selling an estimated $92.2M.
  • Avidity Partners Management's ten largest holdings make up 38% of its $4.71B portfolio in Q4 2021.
  • Avidity Partners Management opened 15 new positions and closed 23 in Q4 2021.
  • Avidity Partners Management's portfolio value rose 4.5% quarter-over-quarter to $4.71B.

Based on Avidity Partners Management's 13F filing for Q4 2021, filed 14 Feb 2022.